Oragenics, Inc. OGEN 深 沪
已收盘 02-06 16:00:00 美东时间
0.732
+0.082
+12.67%
华盛通- 最 高0.7648
- 今 开0.688
- 成交量 16.73万股
- 最 低 0.6348
- 昨 收 0.6497
- 总市值 305.11万
- 52周最高 9.30
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.6321
- 委 比 -33.33%
- 总股本 416.82万
- 历史最高 83700.00
- 量 比 2.12
- 振 幅 20.01%
- 历史最低 0.6321
- 每 手 1
- 风险率 2.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oragenics Showcases Concussion Therapeutic at SCOPE Summit
Oragenics Showcases Concussion Therapeutic at SCOPE Summit Oragenics Inc. will participate in the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute, taking place from February 2-5, 2026, in Orlando, Florida. The company plans to engage with global clinical
02-02 21:30
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Shares of High Roller Technologies Inc (NYSE:ROLR) rose sharply in pre-market t...
01-22 17:46
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
Oragenics, Inc. will present at the Sequire Investor Summit 2026 in Puerto Rico on January 20-22. CEO Janet Huffman highlights the company's novel approach to addressing unmet needs in concussion and mild traumatic brain injury, emphasizing the advancement of their ONP-002 clinical program to Phase 2a studies. Puerto Rico's favorable tax benefits attract many investors, making it an ideal venue for the summit. For more details, visit puertorico.s...
01-14 13:30
Reported November 7, 2025: Oragenics Q3 EPS $(1.96) Up From $(11.32) YoY
Oragenics (AMEX:OGEN) reported quarterly losses of $(1.96) per share. This is a 82.69 percent increase over losses of $(11.32) per share from the same period last year.
2025-11-12 21:38
Oragenics Regains NYSE Compliance After Public Offering
Oragenics ( ($OGEN) ) just unveiled an update. On October 16, 2025, Oragenics s...
2025-10-21 20:17
Oragenics Regains Nasdaq Compliance
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has regained full
2025-10-21 20:01
Oragenics announces partnership with Receptor.AI
Oragenics (NYSE:OGEN) on Tuesday said that it has collaboreted with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the development of its neurological drug pipeli...
2025-10-07 20:41
Oragenics Q2 2025 Shareholder Update
Oragenics, Inc. has achieved significant milestones in developing ONP-002, aiming to become the first FDA-approved pharmacological treatment for concussion. The company's proprietary intranasal delivery technology offers rapid brain delivery, bypassing systemic circulation, and is expected to initiate Phase IIa trials in Q3 2025. Key achievements include human research ethics committee approval, partnerships with Southern Star Research and Sterli...
2025-08-11 12:45
Oragenics Selects Southern Star Research As Clinical Research Organization For Upcoming Phase IIa Clinical Trial Of ONP-002, Lead Drug Candidate For Concussion
Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research
2025-07-31 20:37
